Verve Therapeutics, Inc. has pioneered a transformative approach to combating cardiovascular disease with their gene-editing technology. This breakthrough focuses on permanently altering the PCSK9 gene, which plays a critical role in regulating cholesterol levels. By precisely editing this gene, Verve’s composition effectively lowers harmful LDL cholesterol, offering a potential one-time treatment to prevent heart disease.

The technology hinges on a base editor protein, encoded by mRNA, that targets specific sequences within the PCSK9 gene. Paired with a guide RNA, this protein makes precise edits without causing double-stranded breaks, minimizing risks and improving safety. The guide RNA directs the base editor to the exact location on the gene, where a single nucleotide is altered to disrupt the gene’s function, leading to reduced cholesterol levels.

What sets Verve’s solution apart is its potential for lasting impact. Unlike current treatments that require lifelong medication, this approach offers a durable, possibly permanent, solution by modifying the genetic code itself. The use of lipid nanoparticles ensures that the mRNA and guide RNA are efficiently delivered to liver cells, where the PCSK9 gene is primarily active.

Verve’s gene-editing technology represents a significant leap forward in cardiovascular therapy, moving from managing symptoms to addressing the root cause at the genetic level. This innovation could drastically reduce the burden of cardiovascular disease, potentially eliminating the need for chronic treatments and significantly lowering the risk of heart attacks and strokes. By combining cutting-edge gene editing with targeted delivery, Verve Therapeutics is paving the way for a new era of precision medicine in heart health.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.